Share Price and Basic Stock Data
Last Updated: October 22, 2025, 8:40 am
| PEG Ratio | -1.22 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Elixir Capital Ltd operates in the finance and investments sector, with its share price currently standing at ₹125 and a market capitalization of ₹72.5 Cr. The company has shown a fluctuating revenue trend, with reported sales of ₹4 Cr in FY 2025, a significant increase from ₹35 Cr in FY 2024. Quarterly sales figures have varied considerably, with a peak of ₹18.56 Cr in September 2024, but showing a decline to ₹10.92 Cr in June 2025. The operating profit margin (OPM) reported a notable 38.92% at the end of FY 2025. This oscillation in revenues reflects underlying volatility in the company’s operational performance, which may raise concerns among investors about its revenue sustainability. The company also reported a cash conversion cycle (CCC) of just 0.81 days, suggesting efficient cash management practices, which is a positive indicator in the finance sector.
Profitability and Efficiency Metrics
Elixir Capital’s profitability metrics illustrate a mixed performance. The return on equity (ROE) stood at a commendable 18.0%, while the return on capital employed (ROCE) was reported at 20.1%, indicating effective utilization of capital. The interest coverage ratio (ICR) was robust at 10.26x, suggesting that the company comfortably meets its interest obligations, which is a strong indicator of financial health. However, the net profit for FY 2025 was recorded at ₹13 Cr, a decline from ₹21 Cr in FY 2024, and the earnings per share (EPS) for FY 2025 was noted at ₹16.07, down from ₹26.89 in FY 2024. These figures indicate potential challenges in maintaining profitability amid fluctuating sales and operational expenses, which have also risen significantly in the recent quarters.
Balance Sheet Strength and Financial Ratios
The balance sheet of Elixir Capital demonstrates a stable financial position with total assets reaching ₹115.59 Cr in FY 2025. The company’s reserves increased to ₹50.97 Cr, while borrowings rose to ₹31.32 Cr, resulting in a debt-to-equity ratio of 0.55, indicating a manageable level of debt relative to equity. This is favorable compared to typical industry standards, which often hover around 1.0x. The current ratio was reported at 2.35, and the quick ratio at 0.69, suggesting that while the company has sufficient liquidity to cover its short-term liabilities, it may face challenges in converting its current assets into cash quickly. The price-to-book value (P/BV) ratio stands at 1.38x, reflecting investor perceptions of the company’s value relative to its book value.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Elixir Capital indicates a strong promoter holding of 71.29% as of March 2025, which can be perceived as a positive sign of confidence from the management. The public shareholding accounts for 28.71%, with a total of 4,346 shareholders, reflecting a diverse ownership structure. The absence of Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) may suggest a cautious approach from institutional players. The consistency in promoter holding over the past quarters indicates stability in management; however, the lack of institutional interest could be a concern for potential investors, as institutional backing often signals confidence in a company’s growth prospects. The gradual increase in the number of shareholders from 2,628 in September 2022 to 4,346 in March 2025 may reflect growing retail interest.
Outlook, Risks, and Final Insight
If margins sustain and the company can stabilize its revenue streams, Elixir Capital may position itself favorably within the finance and investments sector. However, the volatility in sales and the decline in net profit present risks that need addressing. If operational efficiencies continue to improve and the company manages its expense growth effectively, there is potential for a rebound in profitability. Additionally, attracting institutional investors could bolster market confidence and provide necessary capital for expansion. Conversely, if the company fails to address its fluctuating revenues and rising operational costs, it may struggle to maintain its current performance levels, impacting shareholder sentiment negatively. Overall, the company’s financial health remains contingent on its ability to manage these challenges while leveraging its strengths in capital efficiency and promoter confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Elixir Capital Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Modern Shares & Stockbrokers Ltd | 12.0 Cr. | 40.8 | 67.7/36.4 | 42.7 | 43.5 | 0.00 % | 3.32 % | 1.74 % | 10.0 |
| Monarch Networth Capital Ltd | 2,508 Cr. | 316 | 495/280 | 16.2 | 102 | 0.32 % | 33.3 % | 26.2 % | 10.0 |
| Monotype India Ltd | 38.0 Cr. | 0.54 | 2.42/0.46 | 3.69 | 0.02 | 0.00 % | 286 % | % | 1.00 |
| Multipurpose Trading & Agencies Ltd | 4.49 Cr. | 9.08 | 12.7/8.25 | 10.3 | 0.00 % | 3.68 % | 3.38 % | 10.0 | |
| Munoth Financial Services Ltd | 25.6 Cr. | 49.9 | 72.0/47.6 | 20.6 | 0.00 % | 2.41 % | 3.38 % | 10.0 | |
| Industry Average | 6,832.37 Cr | 1,434.21 | 134.63 | 3,769.18 | 0.31% | 21.70% | 14.20% | 7.28 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | -3.53 | 7.80 | 0.08 | -0.60 | 4.75 | 6.09 | 5.91 | 15.81 | 14.72 | 18.56 | 6.04 | -3.96 | 10.92 |
| Expenses | 1.34 | 1.53 | 1.31 | 1.51 | 1.57 | 1.68 | 1.62 | 2.41 | 3.04 | 3.00 | 3.70 | 5.59 | 6.67 |
| Operating Profit | -4.87 | 6.27 | -1.23 | -2.11 | 3.18 | 4.41 | 4.29 | 13.40 | 11.68 | 15.56 | 2.34 | -9.55 | 4.25 |
| OPM % | 80.38% | -1,537.50% | 66.95% | 72.41% | 72.59% | 84.76% | 79.35% | 83.84% | 38.74% | 38.92% | |||
| Other Income | 0.28 | 0.05 | 0.17 | 0.24 | 0.34 | 0.89 | 0.22 | 1.20 | 0.27 | 0.16 | 0.22 | -0.13 | 1.17 |
| Interest | 0.22 | 0.28 | 0.33 | 0.30 | 0.34 | 0.40 | 0.33 | 0.45 | 0.43 | 0.56 | 0.66 | 0.38 | 0.62 |
| Depreciation | 0.07 | 0.08 | 0.08 | 0.10 | 0.08 | 0.09 | 0.08 | 0.09 | 0.07 | 0.09 | 0.08 | 0.26 | 0.11 |
| Profit before tax | -4.88 | 5.96 | -1.47 | -2.27 | 3.10 | 4.81 | 4.10 | 14.06 | 11.45 | 15.07 | 1.82 | -10.32 | 4.69 |
| Tax % | 1.43% | 6.04% | -2.72% | 16.74% | 1.61% | 15.38% | 22.44% | 24.32% | 24.98% | 25.08% | 34.62% | -18.22% | 21.54% |
| Net Profit | -4.95 | 5.61 | -1.43 | -2.65 | 3.06 | 4.08 | 3.19 | 10.63 | 8.59 | 11.30 | 1.19 | -8.44 | 3.69 |
| EPS in Rs | -8.53 | 28.98 | -1.77 | -3.38 | 3.89 | 5.39 | 4.07 | 13.54 | 10.94 | 14.41 | 1.52 | -10.80 | 4.70 |
Last Updated: August 19, 2025, 3:48 pm
Below is a detailed analysis of the quarterly data for Elixir Capital Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 10.92 Cr.. The value appears strong and on an upward trend. It has increased from -3.96 Cr. (Mar 2025) to 10.92 Cr., marking an increase of 14.88 Cr..
- For Expenses, as of Jun 2025, the value is 6.67 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.59 Cr. (Mar 2025) to 6.67 Cr., marking an increase of 1.08 Cr..
- For Operating Profit, as of Jun 2025, the value is 4.25 Cr.. The value appears strong and on an upward trend. It has increased from -9.55 Cr. (Mar 2025) to 4.25 Cr., marking an increase of 13.80 Cr..
- For OPM %, as of Jun 2025, the value is 38.92%. The value appears strong and on an upward trend. It has increased from 0.00% (Mar 2025) to 38.92%, marking an increase of 38.92%.
- For Other Income, as of Jun 2025, the value is 1.17 Cr.. The value appears strong and on an upward trend. It has increased from -0.13 Cr. (Mar 2025) to 1.17 Cr., marking an increase of 1.30 Cr..
- For Interest, as of Jun 2025, the value is 0.62 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.38 Cr. (Mar 2025) to 0.62 Cr., marking an increase of 0.24 Cr..
- For Depreciation, as of Jun 2025, the value is 0.11 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.26 Cr. (Mar 2025) to 0.11 Cr., marking a decrease of 0.15 Cr..
- For Profit before tax, as of Jun 2025, the value is 4.69 Cr.. The value appears strong and on an upward trend. It has increased from -10.32 Cr. (Mar 2025) to 4.69 Cr., marking an increase of 15.01 Cr..
- For Tax %, as of Jun 2025, the value is 21.54%. The value appears to be increasing, which may not be favorable. It has increased from -18.22% (Mar 2025) to 21.54%, marking an increase of 39.76%.
- For Net Profit, as of Jun 2025, the value is 3.69 Cr.. The value appears strong and on an upward trend. It has increased from -8.44 Cr. (Mar 2025) to 3.69 Cr., marking an increase of 12.13 Cr..
- For EPS in Rs, as of Jun 2025, the value is 4.70. The value appears strong and on an upward trend. It has increased from -10.80 (Mar 2025) to 4.70, marking an increase of 15.50.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:26 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3.86 | 11.70 | 4.45 | 12.41 | 10.15 | 3.70 | -0.40 | 19.62 | 24.53 | 4.32 | 34.63 | 36.07 | 31.56 |
| Expenses | 1.71 | 1.81 | 2.26 | 2.64 | 3.76 | 3.36 | 3.73 | 4.61 | 5.53 | 5.70 | 7.25 | 15.33 | 18.96 |
| Operating Profit | 2.15 | 9.89 | 2.19 | 9.77 | 6.39 | 0.34 | -4.13 | 15.01 | 19.00 | -1.38 | 27.38 | 20.74 | 12.60 |
| OPM % | 55.70% | 84.53% | 49.21% | 78.73% | 62.96% | 9.19% | 76.50% | 77.46% | -31.94% | 79.06% | 57.50% | 39.92% | |
| Other Income | 0.00 | 0.00 | 1.54 | 0.04 | 0.10 | 0.06 | 0.05 | 0.02 | 0.03 | 0.18 | 0.56 | -0.19 | 1.42 |
| Interest | 0.06 | 0.05 | 0.07 | 0.13 | 0.15 | 0.25 | 0.19 | 0.95 | 1.66 | 1.13 | 1.52 | 2.03 | 2.22 |
| Depreciation | 0.50 | 0.47 | 0.46 | 0.48 | 0.47 | 0.45 | 0.40 | 0.41 | 0.37 | 0.34 | 0.34 | 0.50 | 0.54 |
| Profit before tax | 1.59 | 9.37 | 3.20 | 9.20 | 5.87 | -0.30 | -4.67 | 13.67 | 17.00 | -2.67 | 26.08 | 18.02 | 11.26 |
| Tax % | 29.56% | 29.35% | 24.38% | 25.00% | 28.28% | -10.00% | 10.49% | 10.53% | 23.65% | 28.46% | 19.63% | 29.86% | |
| Net Profit | 1.11 | 6.61 | 2.41 | 6.90 | 4.21 | -0.21 | -3.83 | 12.22 | 12.99 | -3.43 | 20.96 | 12.65 | 7.74 |
| EPS in Rs | 1.40 | 8.43 | 2.89 | 11.89 | 5.36 | -0.36 | -6.60 | 15.72 | 16.54 | -5.91 | 26.90 | 16.08 | 9.83 |
| Dividend Payout % | 121.31% | 20.16% | 11.74% | 10.51% | 23.31% | -345.24% | -18.93% | 7.95% | 7.55% | -21.14% | 4.64% | 7.77% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 495.50% | -63.54% | 186.31% | -38.99% | -104.99% | -1723.81% | 419.06% | 6.30% | -126.40% | 711.08% | -39.65% |
| Change in YoY Net Profit Growth (%) | 0.00% | -559.04% | 249.85% | -225.29% | -66.00% | -1618.82% | 2142.87% | -412.76% | -132.71% | 837.48% | -750.73% |
Elixir Capital Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | % |
| 3 Years: | 14% |
| TTM: | -26% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 35% |
| 3 Years: | 0% |
| TTM: | -69% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 30% |
| 3 Years: | 39% |
| 1 Year: | -11% |
| Return on Equity | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 21% |
| 3 Years: | 17% |
| Last Year: | 18% |
Last Updated: September 5, 2025, 3:21 pm
Balance Sheet
Last Updated: September 10, 2025, 3:35 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.78 | 5.80 | 5.80 | 5.80 | 5.80 | 5.80 | 5.80 | 5.80 | 5.80 | 5.80 | 5.80 | 5.80 |
| Reserves | 9.70 | 13.44 | 13.93 | 17.63 | 21.16 | 19.76 | 14.71 | 22.83 | 31.44 | 28.01 | 42.63 | 50.97 |
| Borrowings | 1.54 | 0.57 | 1.95 | 1.72 | 1.59 | 1.22 | 1.24 | 17.44 | 17.68 | 7.34 | 23.60 | 31.32 |
| Other Liabilities | 6.73 | 8.54 | 8.39 | 11.22 | 11.68 | 11.71 | 16.75 | 26.76 | 27.72 | 26.38 | 24.36 | 27.50 |
| Total Liabilities | 23.75 | 28.35 | 30.07 | 36.37 | 40.23 | 38.49 | 38.50 | 72.83 | 82.64 | 67.53 | 96.39 | 115.59 |
| Fixed Assets | 5.84 | 5.67 | 5.30 | 4.75 | 4.87 | 4.54 | 4.20 | 3.93 | 3.69 | 3.54 | 3.26 | 3.64 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 1.19 | 0.71 | 0.83 | 0.00 | 0.00 | 0.00 | 9.91 | 12.51 | 11.93 | 11.07 | 12.24 | 17.96 |
| Other Assets | 16.72 | 21.97 | 23.94 | 31.62 | 35.36 | 33.95 | 24.39 | 56.39 | 67.02 | 52.92 | 80.89 | 93.99 |
| Total Assets | 23.75 | 28.35 | 30.07 | 36.37 | 40.23 | 38.49 | 38.50 | 72.83 | 82.64 | 67.53 | 96.39 | 115.59 |
Below is a detailed analysis of the balance sheet data for Elixir Capital Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 5.80 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 5.80 Cr..
- For Reserves, as of Mar 2025, the value is 50.97 Cr.. The value appears strong and on an upward trend. It has increased from 42.63 Cr. (Mar 2024) to 50.97 Cr., marking an increase of 8.34 Cr..
- For Borrowings, as of Mar 2025, the value is 31.32 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 23.60 Cr. (Mar 2024) to 31.32 Cr., marking an increase of 7.72 Cr..
- For Other Liabilities, as of Mar 2025, the value is 27.50 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 24.36 Cr. (Mar 2024) to 27.50 Cr., marking an increase of 3.14 Cr..
- For Total Liabilities, as of Mar 2025, the value is 115.59 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 96.39 Cr. (Mar 2024) to 115.59 Cr., marking an increase of 19.20 Cr..
- For Fixed Assets, as of Mar 2025, the value is 3.64 Cr.. The value appears strong and on an upward trend. It has increased from 3.26 Cr. (Mar 2024) to 3.64 Cr., marking an increase of 0.38 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 17.96 Cr.. The value appears strong and on an upward trend. It has increased from 12.24 Cr. (Mar 2024) to 17.96 Cr., marking an increase of 5.72 Cr..
- For Other Assets, as of Mar 2025, the value is 93.99 Cr.. The value appears strong and on an upward trend. It has increased from 80.89 Cr. (Mar 2024) to 93.99 Cr., marking an increase of 13.10 Cr..
- For Total Assets, as of Mar 2025, the value is 115.59 Cr.. The value appears strong and on an upward trend. It has increased from 96.39 Cr. (Mar 2024) to 115.59 Cr., marking an increase of 19.20 Cr..
Notably, the Reserves (50.97 Cr.) exceed the Borrowings (31.32 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 0.61 | 9.32 | 0.24 | 8.05 | 4.80 | -0.88 | -5.37 | -2.43 | 1.32 | -8.72 | 3.78 | -10.58 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 8.51 | 0.00 | 0.82 | 3.24 | 5.75 | 1.97 | -2,646.25 | 0.37 | 5.21 | 21.12 | 2.42 | 0.81 |
| Inventory Days | -7,418.62 | |||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 8.51 | 0.00 | 0.82 | 3.24 | 5.75 | 1.97 | -10,064.88 | 0.37 | 5.21 | 21.12 | 2.42 | 0.81 |
| Working Capital Days | 748.91 | 442.37 | 1,232.80 | 648.53 | 929.94 | 2,434.65 | 3,102.50 | 388.25 | 431.07 | 1,684.75 | 598.25 | 697.42 |
| ROCE % | 7.44% | 38.27% | 6.27% | 29.05% | 16.35% | -0.13% | -13.23% | 32.98% | 29.06% | -2.45% | 36.75% | 20.07% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 16.07 | 26.89 | -4.20 | 16.54 | 15.72 |
| Diluted EPS (Rs.) | 16.07 | 26.89 | -4.20 | 16.54 | 15.72 |
| Cash EPS (Rs.) | 22.64 | 36.70 | -5.32 | 23.00 | 21.78 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 97.83 | 117.55 | 83.14 | 90.74 | 70.07 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 97.83 | 117.55 | 83.14 | 90.74 | 70.07 |
| Revenue From Operations / Share (Rs.) | 60.94 | 56.07 | 6.48 | 39.92 | 33.12 |
| PBDIT / Share (Rs.) | 35.96 | 47.25 | -2.06 | 32.80 | 25.90 |
| PBIT / Share (Rs.) | 35.10 | 46.67 | -2.64 | 32.17 | 25.19 |
| PBT / Share (Rs.) | 31.06 | 44.94 | -4.59 | 29.30 | 23.55 |
| Net Profit / Share (Rs.) | 21.78 | 36.11 | -5.90 | 22.37 | 21.07 |
| NP After MI And SOA / Share (Rs.) | 16.07 | 26.89 | -4.20 | 16.54 | 15.72 |
| PBDIT Margin (%) | 59.00 | 84.27 | -31.82 | 82.16 | 78.20 |
| PBIT Margin (%) | 57.60 | 83.23 | -40.75 | 80.58 | 76.05 |
| PBT Margin (%) | 50.95 | 80.14 | -70.85 | 73.40 | 71.10 |
| Net Profit Margin (%) | 35.74 | 64.40 | -91.11 | 56.04 | 63.62 |
| NP After MI And SOA Margin (%) | 26.37 | 47.96 | -64.80 | 41.42 | 47.47 |
| Return on Networth / Equity (%) | 16.42 | 32.22 | -7.20 | 25.76 | 31.86 |
| Return on Capital Employeed (%) | 25.40 | 39.68 | -3.17 | 35.43 | 35.89 |
| Return On Assets (%) | 8.06 | 16.19 | -3.60 | 11.61 | 12.52 |
| Total Debt / Equity (X) | 0.55 | 0.48 | 0.21 | 0.47 | 0.60 |
| Asset Turnover Ratio (%) | 0.33 | 0.39 | 0.05 | 0.29 | 0.34 |
| Current Ratio (X) | 2.37 | 2.52 | 2.81 | 2.31 | 1.91 |
| Quick Ratio (X) | 0.70 | 0.58 | 1.20 | 0.95 | 0.82 |
| Inventory Turnover Ratio (X) | 0.62 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 10.59 | 6.32 | -40.54 | 10.29 | 11.05 |
| Dividend Payout Ratio (CP) (%) | 10.05 | 6.19 | -47.02 | 9.91 | 10.58 |
| Earning Retention Ratio (%) | 89.41 | 93.68 | 140.54 | 89.71 | 88.95 |
| Cash Earning Retention Ratio (%) | 89.95 | 93.81 | 147.02 | 90.09 | 89.42 |
| Interest Coverage Ratio (X) | 10.26 | 18.02 | -1.06 | 11.44 | 15.81 |
| Interest Coverage Ratio (Post Tax) (X) | 7.37 | 14.43 | -2.03 | 8.80 | 13.86 |
| Enterprise Value (Cr.) | 121.71 | 85.03 | 30.51 | 39.19 | 32.72 |
| EV / Net Operating Revenue (X) | 3.44 | 2.61 | 8.11 | 1.69 | 1.70 |
| EV / EBITDA (X) | 5.83 | 3.10 | -25.50 | 2.06 | 2.18 |
| MarketCap / Net Operating Revenue (X) | 2.21 | 1.58 | 5.28 | 0.95 | 0.86 |
| Retention Ratios (%) | 89.40 | 93.67 | 140.54 | 89.70 | 88.94 |
| Price / BV (X) | 1.38 | 1.06 | 0.58 | 0.59 | 0.57 |
| Price / Net Operating Revenue (X) | 2.21 | 1.58 | 5.28 | 0.95 | 0.86 |
| EarningsYield | 0.11 | 0.30 | -0.12 | 0.43 | 0.54 |
After reviewing the key financial ratios for Elixir Capital Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 16.07. This value is within the healthy range. It has decreased from 26.89 (Mar 24) to 16.07, marking a decrease of 10.82.
- For Diluted EPS (Rs.), as of Mar 25, the value is 16.07. This value is within the healthy range. It has decreased from 26.89 (Mar 24) to 16.07, marking a decrease of 10.82.
- For Cash EPS (Rs.), as of Mar 25, the value is 22.64. This value is within the healthy range. It has decreased from 36.70 (Mar 24) to 22.64, marking a decrease of 14.06.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 97.83. It has decreased from 117.55 (Mar 24) to 97.83, marking a decrease of 19.72.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 97.83. It has decreased from 117.55 (Mar 24) to 97.83, marking a decrease of 19.72.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 60.94. It has increased from 56.07 (Mar 24) to 60.94, marking an increase of 4.87.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 35.96. This value is within the healthy range. It has decreased from 47.25 (Mar 24) to 35.96, marking a decrease of 11.29.
- For PBIT / Share (Rs.), as of Mar 25, the value is 35.10. This value is within the healthy range. It has decreased from 46.67 (Mar 24) to 35.10, marking a decrease of 11.57.
- For PBT / Share (Rs.), as of Mar 25, the value is 31.06. This value is within the healthy range. It has decreased from 44.94 (Mar 24) to 31.06, marking a decrease of 13.88.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 21.78. This value is within the healthy range. It has decreased from 36.11 (Mar 24) to 21.78, marking a decrease of 14.33.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 16.07. This value is within the healthy range. It has decreased from 26.89 (Mar 24) to 16.07, marking a decrease of 10.82.
- For PBDIT Margin (%), as of Mar 25, the value is 59.00. This value is within the healthy range. It has decreased from 84.27 (Mar 24) to 59.00, marking a decrease of 25.27.
- For PBIT Margin (%), as of Mar 25, the value is 57.60. This value exceeds the healthy maximum of 20. It has decreased from 83.23 (Mar 24) to 57.60, marking a decrease of 25.63.
- For PBT Margin (%), as of Mar 25, the value is 50.95. This value is within the healthy range. It has decreased from 80.14 (Mar 24) to 50.95, marking a decrease of 29.19.
- For Net Profit Margin (%), as of Mar 25, the value is 35.74. This value exceeds the healthy maximum of 10. It has decreased from 64.40 (Mar 24) to 35.74, marking a decrease of 28.66.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 26.37. This value exceeds the healthy maximum of 20. It has decreased from 47.96 (Mar 24) to 26.37, marking a decrease of 21.59.
- For Return on Networth / Equity (%), as of Mar 25, the value is 16.42. This value is within the healthy range. It has decreased from 32.22 (Mar 24) to 16.42, marking a decrease of 15.80.
- For Return on Capital Employeed (%), as of Mar 25, the value is 25.40. This value is within the healthy range. It has decreased from 39.68 (Mar 24) to 25.40, marking a decrease of 14.28.
- For Return On Assets (%), as of Mar 25, the value is 8.06. This value is within the healthy range. It has decreased from 16.19 (Mar 24) to 8.06, marking a decrease of 8.13.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.55. This value is within the healthy range. It has increased from 0.48 (Mar 24) to 0.55, marking an increase of 0.07.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.33. It has decreased from 0.39 (Mar 24) to 0.33, marking a decrease of 0.06.
- For Current Ratio (X), as of Mar 25, the value is 2.37. This value is within the healthy range. It has decreased from 2.52 (Mar 24) to 2.37, marking a decrease of 0.15.
- For Quick Ratio (X), as of Mar 25, the value is 0.70. This value is below the healthy minimum of 1. It has increased from 0.58 (Mar 24) to 0.70, marking an increase of 0.12.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.62. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 0.62, marking an increase of 0.62.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 10.59. This value is below the healthy minimum of 20. It has increased from 6.32 (Mar 24) to 10.59, marking an increase of 4.27.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 10.05. This value is below the healthy minimum of 20. It has increased from 6.19 (Mar 24) to 10.05, marking an increase of 3.86.
- For Earning Retention Ratio (%), as of Mar 25, the value is 89.41. This value exceeds the healthy maximum of 70. It has decreased from 93.68 (Mar 24) to 89.41, marking a decrease of 4.27.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 89.95. This value exceeds the healthy maximum of 70. It has decreased from 93.81 (Mar 24) to 89.95, marking a decrease of 3.86.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 10.26. This value is within the healthy range. It has decreased from 18.02 (Mar 24) to 10.26, marking a decrease of 7.76.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.37. This value is within the healthy range. It has decreased from 14.43 (Mar 24) to 7.37, marking a decrease of 7.06.
- For Enterprise Value (Cr.), as of Mar 25, the value is 121.71. It has increased from 85.03 (Mar 24) to 121.71, marking an increase of 36.68.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.44. This value exceeds the healthy maximum of 3. It has increased from 2.61 (Mar 24) to 3.44, marking an increase of 0.83.
- For EV / EBITDA (X), as of Mar 25, the value is 5.83. This value is within the healthy range. It has increased from 3.10 (Mar 24) to 5.83, marking an increase of 2.73.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.21. This value is within the healthy range. It has increased from 1.58 (Mar 24) to 2.21, marking an increase of 0.63.
- For Retention Ratios (%), as of Mar 25, the value is 89.40. This value exceeds the healthy maximum of 70. It has decreased from 93.67 (Mar 24) to 89.40, marking a decrease of 4.27.
- For Price / BV (X), as of Mar 25, the value is 1.38. This value is within the healthy range. It has increased from 1.06 (Mar 24) to 1.38, marking an increase of 0.32.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.21. This value is within the healthy range. It has increased from 1.58 (Mar 24) to 2.21, marking an increase of 0.63.
- For EarningsYield, as of Mar 25, the value is 0.11. This value is below the healthy minimum of 5. It has decreased from 0.30 (Mar 24) to 0.11, marking a decrease of 0.19.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Elixir Capital Ltd:
- Net Profit Margin: 35.74%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 25.4% (Industry Average ROCE: 21.7%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 16.42% (Industry Average ROE: 14.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 7.37
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.7
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 12.1 (Industry average Stock P/E: 134.63)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.55
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 35.74%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Finance & Investments | 58, Mittal Chambers, Mumbai Maharashtra 400021 | cosec@elixirequities.com http://www.elixircapital.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Dipan Mehta | Chairman |
| Mrs. Radhika Mehta | Whole Time Director |
| Mrs. Manori Shah | Independent Director |
| Mr. Shail Kapadia | Independent Director |
FAQ
What is the intrinsic value of Elixir Capital Ltd?
Elixir Capital Ltd's intrinsic value (as of 22 October 2025) is 172.13 which is 39.94% higher the current market price of 123.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 71.6 Cr. market cap, FY2025-2026 high/low of 351/101, reserves of ₹50.97 Cr, and liabilities of 115.59 Cr.
What is the Market Cap of Elixir Capital Ltd?
The Market Cap of Elixir Capital Ltd is 71.6 Cr..
What is the current Stock Price of Elixir Capital Ltd as on 22 October 2025?
The current stock price of Elixir Capital Ltd as on 22 October 2025 is 123.
What is the High / Low of Elixir Capital Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Elixir Capital Ltd stocks is 351/101.
What is the Stock P/E of Elixir Capital Ltd?
The Stock P/E of Elixir Capital Ltd is 12.1.
What is the Book Value of Elixir Capital Ltd?
The Book Value of Elixir Capital Ltd is 97.8.
What is the Dividend Yield of Elixir Capital Ltd?
The Dividend Yield of Elixir Capital Ltd is 1.01 %.
What is the ROCE of Elixir Capital Ltd?
The ROCE of Elixir Capital Ltd is 20.1 %.
What is the ROE of Elixir Capital Ltd?
The ROE of Elixir Capital Ltd is 18.0 %.
What is the Face Value of Elixir Capital Ltd?
The Face Value of Elixir Capital Ltd is 10.0.